FR11C0030I2 - AZTREONAM INHALABLE FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS - Google Patents

AZTREONAM INHALABLE FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS

Info

Publication number
FR11C0030I2
FR11C0030I2 FR11C0030C FR11C0030C FR11C0030I2 FR 11C0030 I2 FR11C0030 I2 FR 11C0030I2 FR 11C0030 C FR11C0030 C FR 11C0030C FR 11C0030 C FR11C0030 C FR 11C0030C FR 11C0030 I2 FR11C0030 I2 FR 11C0030I2
Authority
FR
France
Prior art keywords
aztreonam
treatment
bacterial infections
formulation
pulmonary bacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR11C0030C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22980480&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR11C0030(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of FR11C0030I1 publication Critical patent/FR11C0030I1/fr
Application granted granted Critical
Publication of FR11C0030I2 publication Critical patent/FR11C0030I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli , Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam, or a pharmaceutically acceptable salt thereof, wherein the formulation does not contain arginine or an arginine salt of aztreonam, delivered as an aerosol or dry powder formulation.
FR11C0030C 2000-12-27 2011-08-16 AZTREONAM INHALABLE FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS Active FR11C0030I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25842300P 2000-12-27 2000-12-27
PCT/US2001/050062 WO2002051356A2 (en) 2000-12-27 2001-12-20 Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections

Publications (2)

Publication Number Publication Date
FR11C0030I1 FR11C0030I1 (en) 2011-09-23
FR11C0030I2 true FR11C0030I2 (en) 2012-03-16

Family

ID=22980480

Family Applications (1)

Application Number Title Priority Date Filing Date
FR11C0030C Active FR11C0030I2 (en) 2000-12-27 2011-08-16 AZTREONAM INHALABLE FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS

Country Status (19)

Country Link
US (6) US6660249B2 (en)
EP (2) EP2301524B1 (en)
JP (1) JP4646489B2 (en)
AT (1) ATE502623T1 (en)
AU (1) AU2002231244B2 (en)
BE (1) BE2011C029I2 (en)
BR (1) BRPI0116757B8 (en)
CA (2) CA2708703C (en)
CY (2) CY1111571T1 (en)
DE (2) DE122011100043I1 (en)
DK (2) DK2301524T3 (en)
ES (2) ES2406405T3 (en)
FR (1) FR11C0030I2 (en)
IL (3) IL156596A0 (en)
LU (1) LU91851I2 (en)
NL (1) NL300492I2 (en)
NO (3) NO329643B1 (en)
PT (2) PT2301524E (en)
WO (1) WO2002051356A2 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138419B2 (en) * 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
PT2301524E (en) * 2000-12-27 2013-07-10 Gilead Sciences Inc Inhalable aztreonam without arginine for treatment and prevention of pulmonary bacterial infections
US7214364B2 (en) 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US20030133925A1 (en) * 2001-09-28 2003-07-17 Shawar Ribhi M. Monobactam compositions and methods of use thereof
WO2003075889A1 (en) * 2002-03-05 2003-09-18 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
US7607436B2 (en) 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
EP1527072A1 (en) 2002-08-05 2005-05-04 Teva Gyogyszergyar Reszvenytarsasag Preparation of aztreonam
AU2002356646A1 (en) * 2002-12-11 2004-06-30 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
EP1617820B1 (en) 2003-04-14 2018-03-21 Vectura Limited Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
US7452991B2 (en) 2003-05-15 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Aztreonam β polymorph with very low residual solvent content
EP1624938B1 (en) * 2003-05-20 2011-03-16 James F. Collins Ophthalmic drug delivery system
CA2733145C (en) 2003-07-02 2012-06-19 Corus Pharma, Inc. Aztreonam l-lysine and method of determining impurities therein
AU2014271333B2 (en) * 2003-07-03 2016-10-27 Gilead Sciences, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
AU2004257632C1 (en) * 2003-07-03 2010-04-15 Gilead Sciences, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US7452523B2 (en) * 2004-01-27 2008-11-18 Gilead Sciences, Inc. Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough and tussive attacks
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
EP1888576B1 (en) 2005-05-09 2009-02-18 Sicor Inc. Process for making aztreonam
WO2008039987A2 (en) * 2006-09-28 2008-04-03 Transave, Inc. Methods of treating pulmonary distress
HUP0700007A2 (en) * 2007-01-08 2008-10-28 Asthma Rehabilitacios Ct Kft Device and process for producing of natrium chloride aerosol for the disorders of the respiratory system
US20110038917A1 (en) * 2007-05-08 2011-02-17 Rq Bioscience, Inc. Therapeutic compositions and methods for treating gram-negative bacterial infections
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
US7973029B2 (en) * 2007-10-01 2011-07-05 Gilead Sciences, Inc. Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of-life in lung diseases
RU2527894C2 (en) 2007-11-27 2014-09-10 Альгифарма ИПР АС Using alginate oligomers in biofilm control
EP2098219A1 (en) 2008-03-05 2009-09-09 PARI Pharma GmbH Macrolide compositions having improved taste and stability
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
MX354829B (en) 2009-03-26 2018-03-22 Pulmatrix Operating Co Inc Dry powder formulations and methods for treating pulmonary diseases.
JP5202764B2 (en) 2009-06-03 2013-06-05 アルギファルマ エーエス Alginate oligomers used to overcome multidrug resistance in bacteria
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
AU2011296343B2 (en) 2010-08-30 2015-12-10 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
US20120076859A1 (en) * 2010-09-23 2012-03-29 Activaero Gmbh Targeted Lung Delivery of Citrulline and/or Another Nitric Oxide Precursor and a Method for Treatment of Pulmonary Deficiency of Nitric Oxide in Cystic Fibrosis and Other Pulmonary Diseases
CN107096014B (en) 2010-09-29 2022-07-15 普马特里克斯营业公司 Monovalent metal cation dry powder for inhalation
DK2621488T3 (en) 2010-09-29 2019-03-04 Pulmatrix Operating Co Inc CATIONIC DRY POWDER
EP2804589A1 (en) * 2012-01-16 2014-11-26 Mahmut Bilgic Pharmaceutical formulations comprising aztreonam
CN104487075A (en) 2012-02-29 2015-04-01 普马特里克斯公司 Inhalable dry powders
WO2014158201A1 (en) * 2013-03-28 2014-10-02 Pharmacaribe, Llc Compositions, formulations and methods of bio-balancing the ph of sterile isotonic saline and hypertonic saline solutions
CN105324106A (en) 2013-04-01 2016-02-10 普马特里克斯营业公司 Tiotropium dry powders
CN104784159A (en) * 2015-04-15 2015-07-22 苏州惠仁生物科技有限公司 Method for preparing aztreonam powder aerosol
US11285284B2 (en) 2016-05-03 2022-03-29 Pneuma Respiratory, Inc. Methods for treatment of pulmonary lung diseases with improved therapeutic efficacy and improved dose efficiency
US11285274B2 (en) 2016-05-03 2022-03-29 Pneuma Respiratory, Inc. Methods for the systemic delivery of therapeutic agents to the pulmonary system using a droplet delivery device
US11285283B2 (en) 2016-05-03 2022-03-29 Pneuma Respiratory, Inc. Methods for generating and delivering droplets to the pulmonary system using a droplet delivery device
WO2017192782A1 (en) * 2016-05-03 2017-11-09 Pneuma Respiratory, Inc. Systems and methods comprising a droplet delivery device and a breathing assist device for therapeutic treatment
KR102122887B1 (en) 2016-05-03 2020-06-16 뉴마 레스퍼러토리 인코포레이티드 Droplet delivery device and method of use for delivery of fluids to the waste relationship
EP3634552A4 (en) 2017-05-19 2021-03-03 Pneuma Respiratory, Inc. Dry powder delivery device and methods of use
SG11201911895XA (en) 2017-06-10 2020-01-30 Eyenovia Inc Methods and devices for handling a fluid and delivering the fluid to the eye
CN118203735A (en) 2017-10-04 2024-06-18 精呼吸股份有限公司 Electronic respiration actuated linear type liquid drop conveying device and using method thereof
EP4344719A3 (en) 2017-10-17 2024-06-05 Pneuma Respiratory, Inc. Nasal drug delivery apparatus and methods of use
JP2021502178A (en) 2017-11-08 2021-01-28 ニューマ・リスパイラトリー・インコーポレイテッド In-line droplet delivery device with a small volume ampoule and electrically actuated by breathing and how to use
CN110898040B (en) * 2018-09-18 2022-05-17 北京盈科瑞创新药物研究有限公司 Freeze-dried powder for aztreonam solution for inhalation and preparation method thereof
WO2020174365A1 (en) * 2019-02-28 2020-09-03 Exorao Life Science S.R.L. Sterile aztreonam package
CN111647537B (en) * 2020-06-18 2022-04-26 浙江工业大学 Salt-tolerant capsaicin degrading bacteria, application and kitchen waste treatment method
US11793945B2 (en) 2021-06-22 2023-10-24 Pneuma Respiratory, Inc. Droplet delivery device with push ejection

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126A (en) * 1852-07-13 Marcus r
US610824A (en) * 1898-09-13 Sleigh attachment for vehicles
US572801A (en) * 1896-12-08 Telephone-exchange
US673739A (en) * 1900-09-19 1901-05-07 Frank B Stearns Driving mechanism for vehicles.
US775670A (en) * 1904-08-17 1904-11-22 Thomas F Whittelsey Air-brake safety device.
US946838A (en) * 1909-08-17 1910-01-18 George Dawson Tempering compound.
US4775670A (en) 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
WO1982001873A1 (en) * 1980-12-05 1982-06-10 Takeda Chemical Industries Ltd 1-sulfo-2-oxoazetidine derivatives and process for their preparation
US4673739A (en) 1980-12-05 1987-06-16 Takeda Chemical Industries, Ltd. 4-carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production
US4529698A (en) * 1981-01-19 1985-07-16 E. R. Squibb & Sons, Inc. Process for preparing a 2-oxo-1-azetidinesulfonic acid salt
US4625022A (en) * 1981-02-02 1986-11-25 E. R. Squibb & Sons, Inc. Process for preparing (s)-3-amino-2-oxo-1-azetidinesulfonic acid salts
US4386034A (en) * 1981-02-02 1983-05-31 E. R. Squibb & Sons, Inc. Sulfamated amino acid amides
US4572801A (en) 1981-04-30 1986-02-25 Takeda Chemical Industries, Ltd. 4-Carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production
CA1181075A (en) 1981-07-13 1985-01-15 David M. Floyd CRYSTALLINE ANHYDROUS FORM OF [3-S-[3.alpha.(Z),4 .beta.]]-3-[[(2-AMINO-4-THIAZOLYL) [(1-CARBOXY-1-METHYLETHOXY)IMINO]ACETYL] AMINO]-4-METHYL-2-OXO-1-AZETIDINESULFONIC ACID
US4946838A (en) 1981-07-13 1990-08-07 E. R. Squibb & Sons, Inc. Crystalline anhydrous aztreonam
US4752469A (en) * 1984-01-09 1988-06-21 E. R. Squibb & Sons, Inc. Potentiators of beta-lactam antibiotics
US4826973A (en) * 1984-07-20 1989-05-02 E. R. Squibb & Sons, Inc. Delta form of aztreonam and preparation thereof
US4610824A (en) 1984-10-09 1986-09-09 E. R. Squibb & Sons, Inc. Hydrazide derivatives of monocyclic beta-lactam antibiotics
US4888998A (en) * 1986-07-11 1989-12-26 Beckman Instruments, Inc. Sample handling system
CA1339136C (en) 1987-07-01 1997-07-29 Sailesh Amilal Varia Amorphous form of aztreonam
US5194604A (en) * 1990-06-29 1993-03-16 E. R. Squibb & Sons, Inc. Process and intermediates for beta-lactams having aminothiazole(iminooxyacetic acid)acetic acid sidechains
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
CA2105629A1 (en) * 1992-09-14 1994-03-15 Robert S. Becker Potentiation of immunogenic response
ATE219684T1 (en) * 1994-01-14 2002-07-15 Xoma Technology Ltd ANTI-GRAM POSITIVE BACTERIAL METHODS AND AGENT
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5662929A (en) * 1994-12-23 1997-09-02 Universite De Montreal Therapeutic liposomal formulation
US5723495A (en) 1995-11-16 1998-03-03 The University Of North Carolina At Chapel Hill Benzamidoxime prodrugs as antipneumocystic agents
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
CA2639051A1 (en) 1996-09-04 1998-03-12 Takara Bio Inc. Fungal antigens and process for producing the same
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
CA2410694A1 (en) 1998-06-16 1999-12-16 Serge Dea Porcine reproductive and respiratory syndrome virus (prrsv) dna vaccines
CA2514899A1 (en) 1998-08-31 2000-03-09 Biogen, Inc. Method of modulating memory effector t-cells and compositions
CZ20012147A3 (en) * 1998-12-17 2003-01-15 Chiron Corporation Pharmaceutical preparation in the form of dry powder or atomized aerosol composition for treating chronic bronchitis
AU782493B2 (en) 1999-06-01 2005-08-04 Curis, Inc. Polymer conjugates of hedgehog proteins and uses
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
HU229310B1 (en) * 1999-10-29 2013-10-28 Nektar Therapeutics Dry powder compositions having improved dispersivity
DE19953317C1 (en) 1999-11-05 2001-02-01 Pari Gmbh Aerosol generation unit for inhalation therapies, comprises a valve which allows patient's exhaled air to enter into the surroundings, but prevents direct entry of external air into the mixing chamber during the inhaling phase
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
US7214364B2 (en) * 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
PT2301524E (en) 2000-12-27 2013-07-10 Gilead Sciences Inc Inhalable aztreonam without arginine for treatment and prevention of pulmonary bacterial infections
US7138419B2 (en) * 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
WO2003031163A2 (en) * 2001-10-08 2003-04-17 California Institute Of Technology Microfabricated lenses, methods of manufacture thereof, and applications therefor
WO2003035030A1 (en) 2001-10-24 2003-05-01 Pari Gmbh Kit for the preparation of a pharmaceutical composition
WO2003075889A1 (en) 2002-03-05 2003-09-18 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
EP1417958A1 (en) 2002-11-08 2004-05-12 Pari GmbH Wet granulation process
AU2002356646A1 (en) 2002-12-11 2004-06-30 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
CA2733145C (en) 2003-07-02 2012-06-19 Corus Pharma, Inc. Aztreonam l-lysine and method of determining impurities therein
US7973029B2 (en) 2007-10-01 2011-07-05 Gilead Sciences, Inc. Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of-life in lung diseases

Also Published As

Publication number Publication date
CA2708703C (en) 2012-12-04
BR0116757A (en) 2003-11-04
WO2002051356A2 (en) 2002-07-04
BE2011C029I2 (en) 2021-07-26
IL221036A0 (en) 2012-08-30
US20170296517A1 (en) 2017-10-19
NL300492I2 (en) 2017-11-02
ES2360692T3 (en) 2011-06-08
PT1353647E (en) 2011-05-24
US20030055034A1 (en) 2003-03-20
EP1353647A2 (en) 2003-10-22
US20140037735A1 (en) 2014-02-06
DK2301524T3 (en) 2013-07-15
CA2433280C (en) 2010-09-21
BR0116757B1 (en) 2014-02-04
CY1111571T1 (en) 2014-04-09
CA2433280A1 (en) 2002-07-04
CY2011012I2 (en) 2014-04-09
DE122011100043I1 (en) 2011-12-15
DK1353647T3 (en) 2011-06-14
US7208141B2 (en) 2007-04-24
US20120093890A1 (en) 2012-04-19
LU91851I2 (en) 2011-10-03
EP1353647B1 (en) 2011-03-23
NO20032946D0 (en) 2003-06-26
EP1353647A4 (en) 2007-05-09
CY2011012I1 (en) 2014-04-09
NO20101377L (en) 2003-08-26
US20080050439A1 (en) 2008-02-28
NO2011001I2 (en) 2013-05-27
JP4646489B2 (en) 2011-03-09
ES2406405T3 (en) 2013-06-06
JP2004516302A (en) 2004-06-03
CA2708703A1 (en) 2002-07-04
EP2301524A1 (en) 2011-03-30
IL156596A0 (en) 2004-01-04
EP2301524B1 (en) 2013-04-24
IL156596A (en) 2012-07-31
BRPI0116757B8 (en) 2021-05-25
NO329643B1 (en) 2010-11-22
US6660249B2 (en) 2003-12-09
NO20032946L (en) 2003-08-26
DE60144291D1 (en) 2011-05-05
LU91851I9 (en) 2019-01-03
US20050129623A1 (en) 2005-06-16
PT2301524E (en) 2013-07-10
US9533000B2 (en) 2017-01-03
FR11C0030I1 (en) 2011-09-23
WO2002051356A3 (en) 2002-10-31
NO2011001I1 (en) 2011-02-07
ATE502623T1 (en) 2011-04-15
AU2002231244B2 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
FR11C0030I2 (en) AZTREONAM INHALABLE FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS
CY1114621T1 (en) INSPECTION OF INHIBITED LYSINIC AZRTEONAMINE FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS
WO2011005354A3 (en) Gallium formulation for the treatment and prevention of infectious diseases
Tsuchiya et al. Cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities
BR9303235A (en) COMPOUNDS AND PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL FORMULATION, METHOD FOR COMBATING BACTERIA AND METHOD FOR TREATING BACTERIAL INFECTIONS
US8592473B2 (en) Triazol compounds for treating biofilm formation
JP3005012B2 (en) Antibiotic-resistant staphylococcal infection preventive agent
WO2003097575A3 (en) Amino-functional chalcones
EP1057828A3 (en) Trovafloxacin oral suspensions
PT984019E (en) ANTIBACTERIAL CARBAMATES IN C11 OF MACROLIDOS
Lorenz et al. Efficacy and tolerability of 5-vs 10-day cefixime therapy in acute exacerbations of chronic bronchitis
Janknegt Aminoglycoside therapy: current use and future prospects
CY1114144T1 (en) INHALATED AZRONEONAM FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS
AR040420A1 (en) INHALABLE AZTREONAM FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS
WO2006125123A3 (en) Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
AU2002360218A1 (en) A METHOD OF TREATING BACTERIAL INFECTIONS USING GEMIFLOXACIN OR A SALT THEREOF AND A Beta -LACTAM ANTIBIOTIC
Nagy A new preparation for the treatment of certain bacterial diseases of swine.
Wagenlehner et al. Suitable antibacterial substances for the treatment of urinary tract infections
BR0307468A (en) Antimicrobial Thiadiazinone Derivatives Useful in the Treatment of Bacterial Infections
AR054219A1 (en) FORMULATION OF INHALABLE AZTREONAM LISINATE FOR THE TREATMENT AND PREVENTION OF BACTERIAL PULMONARY INFECTIONS
GR1003520B (en) Methods of use of fluoroquinolone compounds against nosocornial gram negative pathogenic bacteria